Asthika Goonewardene
Stock Analyst at Truist Securities
(2.17)
# 2,903
Out of 5,072 analysts
96
Total ratings
40.66%
Success rate
-3.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $23.05 | +86.55% | 1 | Nov 25, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Hold | $36 → $31 | $27.54 | +11.66% | 6 | Nov 13, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $31.92 | +50.38% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $127.51 | +13.72% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $25.56 | +52.58% | 2 | Oct 7, 2025 | |
| MRUS Merus | Downgrades: Hold | $88 → $97 | $96.09 | +0.95% | 3 | Sep 29, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $34.69 | +188.27% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $77.58 | +27.61% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $44.21 | +10.83% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $102.70 | +50.93% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $27.50 | +158.18% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $1.42 | +604.23% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.37 | +629.93% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $2.44 | +514.75% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.82 | +96.41% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $136 | $73.25 | +85.67% | 5 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $0.89 | +1,592.43% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.59 | +151.57% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.88 | +910.64% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.60 | +4,392.51% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $11.98 | +901.67% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.98 | +2,930.30% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $13.63 | +1,220.62% | 4 | Aug 23, 2022 |
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $23.05
Upside: +86.55%
Mersana Therapeutics
Nov 13, 2025
Downgrades: Hold
Price Target: $36 → $31
Current: $27.54
Upside: +11.66%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $31.92
Upside: +50.38%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $127.51
Upside: +13.72%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $25.56
Upside: +52.58%
Merus
Sep 29, 2025
Downgrades: Hold
Price Target: $88 → $97
Current: $96.09
Upside: +0.95%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $34.69
Upside: +188.27%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $77.58
Upside: +27.61%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $44.21
Upside: +10.83%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $102.70
Upside: +50.93%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $27.50
Upside: +158.18%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $1.42
Upside: +604.23%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.37
Upside: +629.93%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $2.44
Upside: +514.75%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $17.82
Upside: +96.41%
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $73.25
Upside: +85.67%
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $0.89
Upside: +1,592.43%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.59
Upside: +151.57%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.88
Upside: +910.64%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.60
Upside: +4,392.51%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $11.98
Upside: +901.67%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.98
Upside: +2,930.30%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $13.63
Upside: +1,220.62%